Specific inhibitors of the DPP4 (DPP4-Is) have been developed and approved as a therapeutic strategy for T2DM treatment [33] and, more recently, they have been proposed as a first-step therapy in individuals with latent autoimmune diabetes of the adults (LADA) [34], for the broad metabolic pathways mediated by the DPP4/incretin system [35]. Here, GCG is linked to type 2 diabetes mellitus.